MGHNeuroOncology
@MGHNeuroOnc
Followers
518
Following
71
Statuses
147
Stephen E. and Catherine Pappas Center for Neuro-Oncology | Massachusetts General Hospital
Boston, MA
Joined February 2019
RT @MGH_RI: In a new @NEJM study, researchers from @MGHCancerCenter and colleagues found that an approved drug may be repurposed to treat #…
0
6
0
Brigatinib is a treatment option for progressive tumors in NF2-related schwannomatosis. Results from this innovative multi-center, adaptive, platform/basket trial, led by Pappas Center director Dr. Scott Plotkin, are out now in @NEJM.
Brigatinib produced responses in 23% of all tumors in patients with NF2-related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third of patients. Read the full INTUITT-NF2 trial results:
0
0
5
RT @NF2BioSolutions: The recording of our webinar on Avastin Treatment for NF2 with experts Dr. Scott Plotkin and Dr. Gareth Evans is now a…
0
4
0
RT @ShankarLabMGH: Our prospective study now in @BloodJournal! CSF genotyping to facilitate diagnosis of #braintumors. This cell free MYD88…
0
7
0
RT @vlmerker: Calling all #Neurofibromatosis and #Schwannomatosis families in the Boston area! Register for our annual symposium on Saturd…
0
9
0
RT @MGHCancerCenter: Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at…
0
14
0
Congrats to Dr. Bryan Choi, Dr. Elizabeth Gerstner, and the rest of the team on their recent publication in @NEJM! @MGHNeurosurg @braintumor @MGHCancerCenter @MGH_RI
0
0
1
RT @GavinPDunn: Great work from Anthony @anthonyzwang and colleagues on this study! @allegra_petti @MGHNeurosurg @MGHNeuroOnc @MGHCancerCe…
0
8
0
RT @MGH_RI: .@vlmerker is a researcher striving to improve care for patients battling rare diseases like #neurofibromatosis type 1 and schw…
0
3
0
RT @vlmerker: The website for our @MGHNeuroOnc-based NF research group is live! Check out our team, see a sample of our projects and public…
0
2
0
RT @CellDeathLab: Join us October 27th at the JBL Symposium to learn from leaders in neuroscience and radiation oncology including: Helen S…
0
2
0
Register for the annual Miles for Mary 5k Run and Walk on Saturday, October 14th, to support brain tumor research at MGH!
0
0
1
RT @ShankarLabMGH: Truly an honor to present this work at @CNS_Update on behalf of the highly collaborative effort spanning a decade. Chang…
0
9
0
About a year ago and more relevant than ever!
Proud to help lead this consensus review on IDH mutant gliomas and appreciative of the contributions of all of our authors. @MGHNeuroOnc @NeuroOnc
0
0
1
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas | NEJM
0
0
1
Exciting work by Dr. Deborah Forst and colleagues on psychological intervention for caregivers of patients with primary malignant brain tumors:
0
0
1
Congrats to Dr. Jessica Lin and brain tumor team Dr. Nancy Wang, Dr. Helen Shih, and NP Peggy Leland for receiving the IASLC Cancer Care Team Award!
Congratulations to superstar thoracic oncologist Dr. Jessica Lin! @JessicaJLinMD
0
0
1
Celebrating a new academic year together and our four faculty members who were promoted @harvardmed this summer. Congratulations to our new Associate Professors, Justin Jordan and Michael Parsons, and Assistant Professors, Albert Kim and Vanessa Merker!
0
4
24
Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells
0
4
10
Congratulations to Dr. Vanessa Merker @vlmerker for winning the inaugural @REiNScollab Award for Outstanding Service. This international group, co-founded by Pappas Center director Dr. Scott Plotkin, works to improve neurofibromatosis and schwannomatosis clinical trial design.
#REiNS2023 has started! What better way to kick it off than honoring the tremendous efforts of @vlmerker and Miranda McManus to improve #neurofibromatosis care and march towards the goal to #endnf. Congrats to all of the @REiNScollab nominees! Excited to hear groups’ progress!
2
3
14